The study on the relationship between transforming growth factor-β1 and lung carcinoma

AIM: To explore the relationship between the expression of transforming growth factor-β1 (TGF-β1) and the pathogenesis of lung carcinoma, and the influence of radiotherapy on plasma TGF-β1 level of patients with lung carcinoma. METHODS: By immunohistochemical method, the expression of TGF-β1 was examined. An enzyme-linked immunoadsorbent assay (ELISA) was used to quantify the plasma TGF-β1 levels in different time as before radiotherapy, at the end of radiotherapy, and at the time of follow-up 6 months after radiotherapy, respectively. The changes of quantity of TGF-β1 in different time above were analysed statistically. RESULTS: There was a significant increase in TGF-β1 expression in the carcinoma compared with normal lung tissue. The mean TGF-β1 level in the 39 lung carcinoma patients before radiotherapy was (11.0±1.5) μg/L, which was significantly higher than control group (3.8±0.2 μg/L) (P＜0.05); but the plasma TGF-β1 level after radiotherapy was significantly lower (5.6±0.5 μg/L) compared with the level before radiotherapy (P＜0.05), and there was not significant differences compared with control group (P＞0.05). At the time of follow-up 6 months, the patients of lung carcinoma had a significantly higher plasma TGF-β1 level (11.3±1.2 μg/L) compared with the level at the end of radiotherapy (P＜0.05), but there was not significant differences compared with before radiotherapy (P＞0.05). Not significant difference was found in TGF-β1 levels among different histologic types. CONCLUSION: These data demonstrated that TGF-β1 was associated with the pathogenesis of lung carcinoma, and it may be a useful tumor marker in patients with lung carcinoma.